// // TIPO ARTICOLO - Review - Original article -Case report - The Infections in the History of Medicine //


// TITOLO ARTICOLO SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview
// // CICLA PER LISTA AUTORI // // COGNOME E NOME AUTORE //Rabaan Ali A., // COGNOME E NOME AUTORE //Al-Ahmed Shamsah H., // COGNOME E NOME AUTORE //Haque Shafiul, // COGNOME E NOME AUTORE //Sah Ranjit, // COGNOME E NOME AUTORE //Tiwari Ruchi, // COGNOME E NOME AUTORE //Malik Yashpal Singh, // COGNOME E NOME AUTORE //Dhama Kuldeep, // COGNOME E NOME AUTORE //Yatoo M. Iqbal , // COGNOME E NOME AUTORE //Bonilla-Aldana D. Katterine, // COGNOME E NOME AUTORE //Rodriguez-Morales Alfonso J.
The recent outbreak of SARS-CoV-2 that started in Wuhan, China, has now spread to several other countries and is in its exponential phase of spread. Although less pathogenic than SARS-CoV, it has taken several lives and taken down the economies of many countries. Before this outbreak, the most recent coronavirus outbreaks were the SARS-CoV and the MERS-CoV outbreaks that happened in China and Saudi Arabia, respectively. Since the SARS-CoV-2 belongs to the same family as of SARS-CoV and MERS-CoV, they share several similarities. So, this review aims at understanding the new scenario of SARS-CoV-2 outbreak and compares the epidemiology, clinical presentations, and the genetics of these coronaviruses. Studies reveal that SARS-CoV-2 is very similar in structure and pathogenicity with SARS-CoV, but the most important structural protein, i.e., the spike protein (S), is slightly different in these viruses. The presence of a furin-like cleavage site in SARS-CoV-2 facilitates the S protein priming and might increase the efficiency of the spread of SARS-CoV-2 as compared to other beta coronaviruses. So, furin inhibitors can be targeted as potential drug therapies for SARS-CoV.

Page 174-184 - Vol.28 N. 2 - 2020